Top

Published in:

22-03-2024 | Esophagus Resection | Thoracic Oncology

Finding the Optimal Time to Esophagectomy After Systemic Therapy Would be Finding a Lost Princess or Prince

Authors: Markian M. Bojko, MD, MPH, Anthony W. Kim, MD

Published in: Annals of Surgical Oncology | Issue 6/2024

Excerpt

The late and world-renowned surgical oncologist, Dr. Blake Cady, is credited with stating, “Biology is King; selection of cases is Queen, and the technical details of surgical procedures are princes and princesses of the realm who frequently try to overthrow the powerful forces of the King and Queen, usually to no long-term avail, although with some temporary apparent victories.”¹ …

Cady B. Basic principles in surgical oncology. Arch Surg. 1997;132:338–46. https://doi.org/10.1001/archsurg.1997.01430280012001.CrossRefPubMed

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. https://doi.org/10.1056/NEJMoa1112088.CrossRefPubMed

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. https://doi.org/10.1056/NEJMoa055531.CrossRefPubMed

Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.CrossRefPubMed

Li J, Zhou X, Liu Y, et al. Optimal time-to-surgery recommendations based on primary tumor volume regression for patients with resectable esophageal cancer after neoadjuvant chemoradiotherapy: a retrospective study. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-14941-6CrossRefPubMedPubMedCentral

Haisley KR, Laird AE, Nabavizadeh N, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer. JAMA Surg. 2016;151:e162743. https://doi.org/10.1001/jamasurg.2016.2743.CrossRefPubMed

Tsang JS, Tong DKH, Lam KO, et al. Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer. Dis Esophagus. 2017;30:1–8. https://doi.org/10.1093/dote/dox062.CrossRefPubMed

Xiao X, Cheng C, Cheng L, et al. Longer time interval from neoadjuvant chemoradiation to surgery is associated with poor survival for patients without clinical complete response in oesophageal cancer. Ann Surg Oncol. 2023;30:886–96. https://doi.org/10.1245/s10434-022-12758-9.CrossRefPubMed

Nilsson K, Klevebro F, Sunde B, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023;34:1015–24. https://doi.org/10.1016/j.annonc.2023.08.010.CrossRefPubMed

10.

Chiu CH, Chao YK, Chang HK, et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245–51. https://doi.org/10.1245/s10434-013-3139-7.CrossRefPubMed

11.

Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260:807–13. https://doi.org/10.1097/SLA.0000000000000966.CrossRefPubMed

12.

Shaikh T, Ruth K, Scott WJ, et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015;99:270–6. https://doi.org/10.1016/j.athoracsur.2014.08.033.CrossRefPubMed

Title: Finding the Optimal Time to Esophagectomy After Systemic Therapy Would be Finding a Lost Princess or Prince
Authors: Markian M. Bojko, MD, MPH
Anthony W. Kim, MD
Publication date: 22-03-2024
Publisher: Springer International Publishing
Keywords: Esophagus Resection
Esophagus Resection
Esophageal Cancer
Esophageal Cancer
Published in: Annals of Surgical Oncology / Issue 6/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-15173-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Finding the Optimal Time to Esophagectomy After Systemic Therapy Would be Finding a Lost Princess or Prince

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2024

Do Nodal Disease Patterns and Approach to Lymphadenectomy Affect Survival in Patients with Esophageal Squamous Cell Carcinoma? Reinvigorating an Age-Old Debate

Clinicopathological Predictors of Positive Resection Margins in Breast-Conserving Surgery

ASO Visual Abstract: Contemporary Analysis of Re-Excision and Conversion to Mastectomy Rates and Associated Health Care Costs for Women Undergoing Breast-Conserving Surgery

Impact of the COVID-19 Pandemic on the Outcomes of Patients Undergoing Oncological Surgeries: CORONAL Study

Jeffrey A. Norton and the Multiple Endocrine Neoplasia Syndromes

ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial